Impurity Fate Mapping: 5 Documents Buyers Should Request

Abstract: An impurity absent from a Certificate of Analysis is not necessarily absent from the process — it may simply have been purged downstream. This guide explains impurity fate mapping, purge factors, ICH M7 Option 4, and the five documents buyers should request.

The Question Every Buyer Eventually Asks

A sourcing manager reviewing a supplier’s Certificate of Analysis for an intermediate typically finds a handful of specified impurities: known related substances with limits, residual solvents, maybe water content.

Then a technical discussion reveals the route can theoretically form a dozen more impurities — including one with a mutagenic structural alert — and none of them appear on the COA. The question is obvious: why is it acceptable not to test them?

The uncomfortable alternative is equally obvious: a supplier could add every theoretical impurity to the specification, and the COA would list twenty tests, most reporting “not detected,” at a cost passed to the buyer. Neither extreme — blind omission or indiscriminate testing — reflects how modern process chemistry actually controls impurities.

The framework that resolves this question is impurity fate mapping: the systematic assessment of what happens to each impurity at each step of a synthetic route.

It is standard practice inside process development groups at major pharmaceutical companies, it is explicitly recognized by ICH M7, and it is almost never explained to the buyers who purchase intermediates.

This guide closes that gap — what fate mapping is, how purge factors work, when untested really means uncontrolled versus justified, and exactly which documents to request from a supplier.

What Impurity Fate Mapping Is

Every impurity in a synthetic process has one of three fates at each step:

• Purged: removed from the product stream — destroyed by the reaction conditions, partitioned into an aqueous wash, left in the mother liquor during crystallization, or volatilized during drying or distillation.
• Carried through: survives the step and moves with the product to the next operation.
• Reacted out: consumed by the following chemistry — converted into the product itself or into a different (ideally benign) species.

Fate mapping is the exercise of assigning one of these fates to every known and potential impurity at every step, then multiplying the results. A four-step route from starting material to the intermediate you purchase is, from the impurity’s point of view, four consecutive filters. An impurity formed in step one that loses 99% per step arrives at your drum with 0.0001% of its original level — one part per million of one percent.

This is why an impurity can be genuinely well controlled without ever appearing on a COA. It is also why the same claim, made without documentation, can be a smokescreen. The difference between science and slogan is the paper.

A Worked Example

Consider a simplified route: a starting material containing a mutagenic alkyl halide residue at 500 ppm undergoes two chemical steps and one crystallization before isolation of your intermediate.

Overall purge: 1000×. An impurity entering at 500 ppm leaves at 0.5 ppm — below the 1.5 μg/day acceptable intake threshold for a mutagenic impurity at typical daily doses, without a single dedicated test on the COA. The numbers above are deliberately conservative; real reactions that consume a reactive halide routinely achieve far higher clearances.

Published industry assessments of purge behavior (Teasdale et al., Organic Process Research & Development, 2010 and 2013) built exactly this kind of conservative, factor-based logic into a framework now embedded in tools such as the Mirabilis purge database maintained by an industry consortium.

The Purge Factor: How Clearance Is Quantified

A purge factor is the ratio of an impurity’s level before an operation to its level after. The concept matters to buyers for one reason: it converts “trust us, it’s cleared” into arithmetic that can be reviewed, challenged, and defended in an audit.

Different unit operations purge differently, and the industry consensus factors reflect this:

Two principles govern credible purge assessments. First, factors must be conservative — a well-run crystallization might clear 50×, but the assessment assumes the low end, so that real-world variability (a rushed filtration, a colder solvent, a different batch of charcoal) stays inside the margin.

Second, factors must be mechanistically justified: claiming crystallization purge for an impurity known to co-crystallize, or claiming reaction purge for an impurity that is inert under the conditions, invalidates the whole calculation. This is why a purge justification is a document, not a sentence.

ICH M7 Option 4: When “Not Tested” Is Regulatorily Sound

ICH M7, the guideline for assessment and control of mutagenic impurities in drug substances and drug products, defines four control options:

Option 4 is the direct regulatory ancestor of fate mapping as a control strategy. It says, in effect: if you understand your process well enough to demonstrate — with conservative assumptions — that an impurity cannot survive to the final API at a relevant level, you do not need to test for it.

For high-volume products, this is not a loophole; it is the only proportionate strategy. Testing every theoretical mutagen in every batch would consume more analytical capacity than the industry possesses.

But Option 4 carries conditions that matter to buyers:

• The rationale must exist in writing. Not “our chemists looked at it” — a documented assessment with purge logic and predicted residual levels.
• Assumptions must be conservative, so that process variability does not silently consume the safety margin.
• The justification dies with the process. Change the route, the raw material source, or a solvent system, and the fate map must be redrawn. This is where change notification clauses in supply agreements become an impurity control, not boilerplate.

Note also that fate mapping is not exclusive to mutagenic impurities. The same logic underpins residual solvent control (ICH Q3C: solvents are purged by drying and reaction steps, which is why Class 2 solvents from early steps rarely appear on late-intermediate COAs) and, in a modified form, elemental impurity control (ICH Q3D: catalyst residues such as palladium from a hydrogenation step are controlled by scavenging and filtration — see our elemental impurities guide).

Case Study: Fate Mapping at Merck — the Verubecestat Process

The best public illustration of fate mapping as a development discipline comes from Merck’s published work on verubecestat (MK-8931), the BACE inhibitor that reached Phase 3 for Alzheimer’s disease.

In Organic Process Research & Development (2019), Merck analytical and process chemists described using a low-cost single quadrupole mass spectrometer to identify and track process impurities through the multistep synthesis — explicitly noting that process optimization decisions were driven by the type, quantity, and final fate of impurities generated at each stage (Zewge et al., OPRD, 2019).

Three lessons for intermediate buyers emerge from this and similar published studies:

1. The best process teams in the industry track impurity fate early, not late. Fate mapping guided route selection during development — it was never an after-the-fact justification. A supplier who cannot discuss impurity fate has not done this work.
2. Tracking tools matter less than tracking discipline. Merck used a compact, inexpensive benchtop instrument. A mid-sized Chinese intermediate manufacturer with a modest LC-MS can run the same discipline. What separates suppliers is whether the fate data is captured, filed, and reflected in specifications — not the brand of the instrument.
3. Fate mapping changes specifications. When an impurity’s fate showed it carried through rather than purged, the process was changed or the impurity was controlled explicitly. The fate map and the COA should tell one coherent story.

What Fate Mapping Means When You Are Buying Mid-Route

An intermediate buyer occupies a specific point on someone else’s fate map, and this creates an asymmetry worth stating plainly:

• Everything upstream of your purchase is the supplier’s documented responsibility. The purge history from starting material to your drum should exist in the supplier’s files, and you are entitled to see its summary.
• Everything downstream of your purchase is your process’s purge capacity. If you run one crystallization from the intermediate to the API, an impurity surviving at 50 ppm has one filter left. If you run three steps, it has three. The same intermediate specification can be perfectly adequate for one buyer and inadequate for another.

This is why the number of remaining synthetic steps — not the purity percentage — is often the more consequential number in an intermediate datasheet. A 99.0% intermediate three steps from the API with a documented purge path may pose less risk than a 99.5% intermediate one step away with unknown impurity fates.

Buyer diligence should therefore include where the material sits in the route, which is also central to ICH Q11 starting material selection — the guideline that determines how far upstream regulatory responsibility extends.

The Five Documents to Request From a Supplier

Fate mapping turns a vague question (“is this material clean?”) into specific, auditable requests. When qualifying or auditing an intermediate supplier, ask for these five items:

1. Potential Impurity List with Structural Alert Screening

Every impurity the route can theoretically form — starting material residues, byproducts, reagent residues, degradants — flagged for mutagenic structural alerts. Without this list, no purge assessment can begin, and the COA’s tested items are a sample of an unknown population. For context on reading what the COA does show, see our guide to reading a pharmaceutical intermediate COA.

2. The Purge Justification

A written document — even one page — assigning each impurity its fate per step, using conservative factors, and concluding with predicted residual levels against the applicable thresholds. Impurities justified by ICH M7 Option 4 should be identifiable in this document by name. For the nitrosamine class, where acceptable intakes are measured in parts per billion and regulatory scrutiny is intense, purge arguments must be correspondingly stronger — our nitrosamine risk guide covers that special case.

3. Remaining Steps Information

How many synthetic operations remain between the intermediate sold to you and the final API, in general terms. This defines the residual purge capacity that your own process inherits and determines which upstream impurities are genuinely your problem. Suppliers can share step counts and operation types without disclosing full chemistry.

4. The Option 4 Exemption List

Which specific impurities are controlled by purge rationale rather than by testing, cross-referenced to the justification. This is the list a competent supplier updates when the route changes — and the list an auditor asks for first. It complements, not replaces, the general impurity control strategy described in our article on impurity control in pharmaceutical intermediates.

5. Change Notification Commitment

A contractual clause requiring the supplier to notify you before any change to route, raw material source, or process parameters that could affect the fate map.

This is where fate mapping stops being chemistry and becomes supply chain governance: the purge justification for yesterday’s batches is worthless if tomorrow’s batches follow a different route. Frame these requests within a structured supplier audit checklist so they are evaluated consistently across vendors.

Red Flags: When “It’s Purged” Means “We Haven’t Looked”

None of these red flags requires the buyer to be a synthetic chemist. Each one is a test of whether documentation exists and hangs together — the same skill you already apply when reviewing whether an analytical method on a COA was validated per ICH Q2.

Conclusion: The COA Is a Conclusion, Not the Evidence

A Certificate of Analysis tells you what was tested and what the results were. Impurity fate mapping explains why the list of tested things is the right list — which impurities were consumed by the chemistry, discarded with the mother liquor, or partitioned into the wash, and which ones genuinely required a limit and a method.

The strongest suppliers can tell this story for every material they sell, with documents behind it. The weakest hide behind either a suspiciously short specification or a uselessly long one.

For buyers, the practical takeaway is a shift in questioning. Instead of “what is your purity?”, ask “show me the fate map”. The answer — or the inability to produce one — tells you more about a supplier’s real quality culture than any certificate on the wall.

Want a supplier who can show you the fate map? Tianming Pharm manufactures pharmaceutical intermediates with documented impurity control: potential impurity lists with structural alert screening, written purge justifications for Option 4 controlled impurities, lot-specific COAs, and change notification commitments written into supply agreements.

We publish our route logic and impurity reasoning because we did the work — request the documentation package for your material. Contact our technical team.